Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Jiangsu Joint International Research Laboratory of Chinese Medicine and Regenerative Medicine, Nanjing, China.
Front Immunol. 2021 Oct 21;12:747914. doi: 10.3389/fimmu.2021.747914. eCollection 2021.
The human body and its microbiome constitute a highly delicate system. The gut microbiome participates in the absorption of the host's nutrients and metabolism, maintains the microcirculation, and modulates the immune response. Increasing evidence shows that gut microbiome dysbiosis in the body not only affects the occurrence and development of tumors but also tumor prognosis and treatment. Microbiome have been implicated in tumor control in patients undergoing anti- angiogenesis therapy and immunotherapy. In cases with unsatisfactory responses to chemotherapy, radiotherapy, and targeted therapy, appropriate adjustment of microbes abundance is considered to enhance the treatment response. Here, we review the current research progress in cancer immunotherapy and anti- angiogenesis therapy, as well as the unlimited potential of their combination, especially focusing on how the interaction between intestinal microbiota and the immune system affects cancer pathogenesis and treatment. In addition, we discuss the effects of microbiota on anti-cancer immune response and anti- angiogenesis therapy, and the potential value of these interactions in promoting further research in this field.
人体及其微生物组构成了一个高度精细的系统。肠道微生物组参与宿主营养物质的吸收和代谢，维持微循环，并调节免疫反应。越来越多的证据表明，体内肠道微生物组失调不仅影响肿瘤的发生和发展，还影响肿瘤的预后和治疗。微生物组与接受抗血管生成治疗和免疫治疗的患者的肿瘤控制有关。在化疗、放疗和靶向治疗反应不佳的情况下，考虑适当调整微生物丰度以增强治疗反应。在这里，我们综述了癌症免疫治疗和抗血管生成治疗的最新研究进展，以及它们联合应用的无限潜力，特别是重点讨论了肠道微生物群与免疫系统的相互作用如何影响癌症的发病机制和治疗。此外，我们还讨论了微生物群对抗肿瘤免疫反应和抗血管生成治疗的影响，以及这些相互作用在促进该领域进一步研究方面的潜在价值。
